CDXS - コデクシス (Codexis Inc.) コデクシス

 CDXSのチャート


 CDXSの企業情報

symbol CDXS
会社名 Codexis Inc (コデクシス)
分野(sector) Basic Industries   素材
産業(industry) Major Chemicals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コデクシス(Codexis Inc.)はタンパク質エンジニアリング会社である。同社は、医薬品およびファインケミカルの商業用製造のための生体触媒の開発に従事している。同社はパフォーマンス酵素及び新規の生物療法剤2つの事業を運営する。同社は、小規模から商業的な量までの酵素最適化サービスを提供し、また生体触媒製品を開発する。また、活性医薬成分、ファインケミカル、食品成分の製造プロセスの開発に従事する。同社のCodeEvolverは、タンパク質工学の技術プラットフォームであり、医薬品市場における製品である。同社は、食品および食品原料、動物飼料、香料、香料及び農薬を含む各産業にサービスを提供する。   コデクシスは米国のバイオテクノロジ―企業。医薬品及び精製化学製品市場のための生体触媒を開発、生産。製薬会社のほか、食品、動物飼料、ポリマ―、香味及び香料、農薬などの製造会社に、生体触媒である酵素を提供する。同社は2002年に設立し、カリフォルニア州に本社を置く。   
本社所在地 200 Penobscot Drive Redwood City CA 94063 USA
代表者氏名 Bernard J. Kelley バーナード・J.・ケリー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-421-8100
設立年月日 37257
市場名 NASDAQ National Market System
ipoyear 2010年
従業員数 116人
url www.codexis.com
nasdaq_url https://www.nasdaq.com/symbol/cdxs
adr_tso
EBITDA EBITDA(百万ドル) -16.71000
終値(lastsale) 16.5
時価総額(marketcap) 882953791.5
時価総額 時価総額(百万ドル) 917.73680
売上高 売上高(百万ドル) 59.28700
企業価値(EV) 企業価値(EV)(百万ドル) 864.29880
当期純利益 当期純利益(百万ドル) -51.78500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Codexis Inc. revenues increased 51% to $27.6M. Net loss decreased 39% to $8.4M. Revenues reflect EMEA segment increase of 70% to $8.8M America segment increase of 56% to $9.7M. Lower net loss reflects Interest income increase from $67K to $245K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.31 to -$0.17.

 CDXSのテクニカル分析


 CDXSのニュース

   Codexis and Kalsec expand research collaboration agreement  2021/07/26 20:15:42 Seeking Alpha
   Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient  2021/07/26 20:05:00 Intrado Digital Media
REDWOOD CITY, Calif. and KALAMAZOO, Mich., July 26, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection and hop extracts for the food and beverage industry, announced that the companies have expanded their research collaboration and entered into an exclusive supply agreement for a novel enzyme to produce Kalsecs newest natural hop acid.
   Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader  2021/07/14 20:05:00 Intrado Digital Media
REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver ® platform technology transfer with Novartis Pharma AG (Novartis) today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver ® to develop novel performance enzymes for use in the manufacture of pharmaceutical products.
   Codexis Earns Milestone Payment from GlaxoSmithKline  2021/07/07 20:05:00 Intrado Digital Media
REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter.
   Should You Expect A Quick Recovery From Codexis, Inc. (NASDAQ:CDXS) After -31.14% Decline From High?  2021/06/26 08:32:00 Investor Newsletter
Codexis, Inc. (NASDAQ:CDXS)s traded shares stood at 636,886 during the last session, with the companys beta value hitting 1.27. At the close of trading, the stocks price was $22.54, to imply an increase of 0.94% or $0.21 in intraday trading. The CDXS shares 52-week high remains $29.56, putting it -31.14% down since that peak but []
   TSMC, BYD, Komatsu, Surface Oncology And 3D Systems — What Cathie Wood's Ark Bought And Sold Today  2021/03/24 03:47:13 Benzinga
Every night, Cathie Wood’s Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause certain stocks to see a spike in the after-hours session. Here’s a list of what the hedge fund bought or sold on Tuesday. 3D Systems Corp (NYSE: DDD ): Bought 558,900 shares of the printing engineering company, representing about 0.46% of the ETF. 3D shares closed 9.62% lower at $26.22 on Tuesday and rose 1.07% in the after-hours. It has a 52-week high of $56.5 and low of $4.60. Accolade Inc (NASDAQ: ACCD ): Bought 38,112 shares of the personalized health-tech company, representing about 0.016% of the company. Accolade shares closed 2.2% lower at $42.03 on Tuesday and were further down 1.26% in the after-hours. It has a 52-week high of $62.25 and low of $28.68. Codexis Inc (NASDAQ: CDXS ): Bought 138,712 shares in the protein engineering company, representing just about 0.032% of the ETF. Codexis shares closed 2.44% lower at $21.95 on Tuesday.
   Global Proteinase K Market Analysis Report 2020-2027 Featuring Key players - Merck, BBI Solutions, Codexis, SBS Genetech, Hoffmann-La Roche, Amicogen Amano Enzyme & Advanced Enzymes Technologies - ResearchAndMarkets.com  2021/03/01 13:33:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area; By Form, By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global proteinase K market size is predicted to reach US$ 107.5 Million by 2027 The report "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Infectious diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, N
   Phenylketonuria Treatment Market Analysis Released in Latest Industry Report 2020: BioMarin, Codexis, Erytech Pharma, SOM Innovation Biotech, Retrophin  2021/02/26 08:08:42 OpenPR
Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Phenylketonuria Treatment market with detailed
   Codexis Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2021/02/24 21:24:00 Stock Market Daily
Codexis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Codexis (CDXS) may be moving closer to profitability, after beating slowdown  2021/01/21 18:34:23 AlphaStreet
Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to the virus crisis. The recent improvement in fiscal […] The post Codexis (CDXS) may be moving closer to profitability, after beating slowdown first appeared on AlphaStreet .
   Codexis (CDXS) may be moving closer to profitability, after beating slowdown  2021/01/21 18:34:23 AlphaStreet
Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to the virus crisis. The recent improvement in fiscal […] The post Codexis (CDXS) may be moving closer to profitability, after beating slowdown first appeared on AlphaStreet .
   Global Biocatalysis and Biocatalyst Suppliers Leadership & Benchmark Report 2020-2021 Featuring Dupont, Royal DSM N.V., Codexis Inc., BASF, AB Enzymes, Amano Enzymes, Novozymes A/S, and Chr. Hansen - ResearchAndMarkets.com  2021/01/07 08:23:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Leadership Quadrant of Biocatalysis and Biocatalyst Suppliers - 2021" report has been added to ResearchAndMarkets.com's offering. The biocatalysis and biocatalyst manufacture landscape is diverse and continually evolving. Major players in the the the the the biocatalysis and biocatalyst market have diversified product portfolios, strong geographical reach, and have made several strategic initiatives. The dynamics of the biocatalysis and biocatalyst market extends b
   Why BlackRock Stock Will Continue to Rock  2021/01/01 00:31:00 Yahoo Finance
Organic growth and strong cash inflows should keep the company atop the asset-management pyramid. Also, Wall Street views on Codexis, IMAX, Alibaba, and Intel
   Codexis Announces Pricing of Public Offering of Common Stock - Stocks News Feed  2020/12/03 04:11:00 Stocks News Feed
REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $17.50 per share. Net proceeds to Codexis from the offering are expected to be approximately $70.2… Read More »Codexis Announces Pricing of Public Offering of Common Stock
   Reviewing Codexis (NASDAQ:CDXS) & New Oriental Energy & Chemical (NASDAQ:NOEC)  2020/10/24 12:12:50 Dakota Financial News
Codexis (NASDAQ:CDXS) and New Oriental Energy & Chemical (OTCMKTS:NOEC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings & Valuation This table compares Codexis and New Oriental Energy & Chemical’s gross […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コデクシス CDXS Codexis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)